Year 2019 / Volume 111 / Number 10
Original
Definition of the profiles of hepatitis C virus patients based on the identification of risky practices in Spain

731-737

DOI: 10.17235/reed.2019.6169/2019

Jose Luis Calleja Panero, Sabela Lens García, Miguel Fernández Bermejo, Javier Crespo,

Abstract
The absolute number of patients infected with the hepatitis C virus and its prevalence in Spain according to risk practices are not precise. The objective of the study was to estimate the current direct-action antiviral candidates, according to risky practices. The exposed population was determined according to each risky practice and age, based on the data obtained in two epidemiological studies and other bibliographic sources. The overall prevalence of positive serology for the Hepatitis C virus according to the analyzed data was 1.1% (41% with an active infection). The most at-risk group are intravenous drug users (60,368-82,454). It is estimated that between 37,387 to 51,065 patients would be infected via sexual transmission, between 55,505 and 75,812 patients following a blood transfusion and around 18,528 to 25,307 patients by socio-family transmission. According to these data, more than half (55-79%) of the subjects with risky practices would have significant fibrosis (≥ F2). It is estimated that more than half a million people have a positive serology for the Hepatitis C virus and 144,191 to 227,773 antiviral treatments are expected in the coming years. The identification of people with risky practices is key to increase the percentage of diagnosed cases.
Share Button
New comment
Comments
No comments for this article
References
1. Bruguera M, Forns X. Hepatitis C in Spain. Med Clin (Barc) 2066; 127: 113-117.
2. Sacristan B, Gastañares MI, Elena A et al. Estudio seroepidemiológico de la hepatitis C en una población general de La Rioja. Med Clinica. 1996; 107: 331-335.
3. García-Fulgueiras A, Tormo MJ, Rodríguez T et al. Prevalence of hepatitis B and C markers in the South East of Spain: An unlinked community based survey of 2203 adults. Scand J Infect Dis. 1996; 28: 17-20.
4. Riestra S, Fernández E, Leiva P et al. Prevalence of hepatitis C virus infection in the general population of Northern Spain. Eur J Gastroenterol Hepatol. 2001; 13: 477-481.
5. Chimeno MM, Chocarro A, Brezmes P et al. Seroprevalencia del virus de la hepatitis C en la población general. Enferm Infecc Microbiol Clin. 2002; 20: 64-67.
6. Solà R, Cruz de Castro E, Hombrados M et al. Prevalence of hepatitis B and hepatitis C viruses in different counties of Catalonia, Spain: Cross-sectional study. Med Clin (Barc). 2002; 119: 90-95.
7. Lopez Izquierdo R, Udaondo MA, Zarzosa P et al. Seroprevalence of viral hepatitis in a representative general population of an urban public health area in Castilla y León (Spain). Enferm Infecc Microbiol Clin. 2007; 25: 317-323
8. Gower E, Estes C, Blach S et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014; 61: S45-57.
9. Bruggmann P, Berg T, Ovrehus AL et al. Historical epidemiology of hepatitis C virus (HCV) in selected countries. J Viral Hepatitis. 2014; 21: 5-33.
10. Calleja JL, Llop E, Ruiz M et al. Prevalencia de marcadores serológicos de virus hepatotropos (By C) en población trabajadora sana. Rev Esp Enferm Dig; 5;249-254; 2013.
11. Gower E. et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. Journal of Hepatology 2014 vol. 61 j S45–S57
12. Bruggmann P. et al. Historical epidemiology of hepatitis C virus (HCV) in selected countries. Journal of Viral Hepatitis, 2014, 21, (Suppl. 1), 5–33
13. Nota de prensa del MSSSI publicada el 11 Oct-2016.
14. Buti M, Franco A, Carmona I et al. Profiles and clinical management of hepatitis C patients in Spain: disHCovery study. Rev Esp Quimioter 2015; 28(3): 145-153.
15. Cuadrado A, Perelló C, Llerena S et al. Estudio de la prevalencia de la hepatitis C en la población española. Estudio PREVHEP/COHORTE ETHON. Presentación oral en el 42 Congreso de la Asociación Española para el Estudio del Hígado (AEEH).
16. World Health Organization. Guidelines for the screening, care and treatment of persons with hepatitis C infection. Geneva: World Health Organization; April 2014 Mühlberger N, Schwarzer R, Lettmeier B, Sroczynski G, Zeuzem S, Siebert U. HCV-related burden of disease in Europe: A systematic assessment of incidence, prevalence, morbidity, and mortality. BMC Public Health. 2009; 9:34.
17. Alonso S, Agudo S, García A et al. Seroprevalencia de hepatitis C en población con factores de riesgo del suroeste de la comunidad de Madrid. Gastroenterol Hepatol. 2016; 39(10):656-662.
18. Rodríguez-Tajes S, Dacal Y, Collazos C et al. Estudio de prevalencia de infección por los virus hepatitis B y C en Cataluña. Presentación oral en el 42 Congreso de la Asociación Española para el Estudio del Hígado (AEEH).
19. Fernández-Bermejo M, Íñiguez R, Mata P et al. Estudio de prevalencia de serología de hepatitis C en un área de salud con población rural. Póster en el 42 Congreso de la Asociación Española para el Estudio del Hígado (AEEH).
20. Thein H-H, Yi Q, Dore GJ et al. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: A meta-analysis and meta-regression. Heapatology 2008; 48 (2): 418-431.
21. Yi Q, Wang PP, Krahn M. Improving the accuracy of long-term prognostic estimates in hepatitis C virus infection. J Viral Hepat 2004;11:166-174.
22. Observatorio Español de las drogas y las toxicomanías. Informe 2016. Alcohol, tabaco y drogas ilegales en España. Ministerio de Sanidad, Servicios Sociales e igualdad. Secretaría de estado de servicios sociales e igualdad. 2017.
23. McDonald SA, Dahlui M, Mohamed R et al. Projections of the Current and Future Disease Burden of Hepatitis C Virus Infection in Malaysia. PLoS ONE 2015; 10(6).
24. Resultados de la Encuesta Nacional de Salud Sexual en España, 2009. Consulta on-line http://www.msps.es/mwg-internal/de5fs23hu73ds/progress?id=AXPEqxALFz9Vccc5Tfj1RudTM6VGh0GPfXcAOw-w0u8, 15 julio 2017.
25. Muñoz Gámez JA, Díaz Alcázar, MM, Salmerón Escobar J et al. Prevalencia y epidemiología del VHB y VHC en mujeres españolas embarazadas y en edad. Póster en el 42 Congreso de la Asociación Española para el Estudio del Hígado (AEEH).
26. Dibba P, Cholankeril R, Li AA et al. Hepatitis C in pregnancy. Diseases. 2018 ; 6: 31. doi:10.3390/diseases6020031
27. Roncero C, Vega P, Martinez-Raga J et al. Chronic Hepatitis C and people with a history of injecting drugs in Spain: population assessment, challenges for effective treatment. Adicciones. 2017 Apr 11;29:71-73. doi: 10.20882/adicciones.908.
28. Associació catalana de malalts hepatics (ASSCAT). El impacto del diagnóstico de hepatitis C en las conductas de uso de sustancias en pacientes que participan en la terapia de sustitución de opioides | Noticias de prensa 31/10/2017.
29. Jozaghi E, Lampkin H, Andresen MA. Peer-engagement and its role in reducing the risky behavior among crack and methamphetamine smokers of the Downtown Eastside community of Vancouver, Canada. Harm Reduct J. 2016; 8:19. doi: 10.1186/s12954-016-0108-z.
30. Macías J, Palacios RB, Claro E et al. High prevalence of hepatitis C virus infection among noninjecting drug users: association with sharing the inhalation implements of crack. Liver Int. 2008;28:781-6. doi: 10.1111/j.1478-3231.2008.01688.x.
31. Hepatitis C Support Project, hoja informativa Sexual Transmission of Hepatitis C Septiembre de 2010. Consulta on-line www.hcvadvocate.org; 15 julio 2017.
32. ChemSex y hepatitis C: una guía para profesionales sanitarios, adaptación libre al español de un material elaborado por David Stuart de 56 Dean Street por parte del Grupo de Trabajo sobre Tratamientos del VIH.
33. González-Baeza A, Dolengevich-Segal H, Pérez-Valero I et al. Sexualized Drug Use (Chemsex) Is Associated with High-Risk Sexual Behaviors and Sexually Transmitted Infections in HIV-Positive Men Who Have Sex with Men: Data from the U-SEX GESIDA 9416 Study. AIDS Patient Care STDS. 2018 Mar;32:112-118. doi: 10.1089/apc.2017.0263.
34. Ministerio de Sanidad, Servicios Sociales e Igualdad. Plan estratégico para el abordaje de la hepatitis C en el sistema nacional de salud. Madrid. Mayo 2015.
35. Ministerio de Sanidad, Servicios Sociales e Igualdad. Plan estratégico para el abordaje de la hepatitis C en el sistema nacional de salud. Madrid. Agosto 2017.
36. Nota de prensa del MSSSI publicada el 23 Feb-2016.
37. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2ª plus rivabirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347 (13): 975-982.
38. Paintsil E, Binka M, Patel A et al. Hepatitis C Virus Maintains Infectivity for Weeks after Drying on Inanimate Surfaces at Room Temperature: Implications for Risks of Transmission. J Infect Dis 2014; 209 (8): 1205-1211.
39. Paintsil E, He H, Peters C et al. Survival of Hepatitis C Virus in Syringes: Implication for Transmission among Injection Drug Users. J Infect Dis. 2010; 202 (7): 984–990.
Related articles

Editorial

Cases of liver disease lost in the health system: a call to action

DOI: 10.17235/reed.2021.8316/2021

Original

Active search for hepatitis C patients in primary care

DOI: 10.17235/reed.2021.8067/2021

Original

Hepatitis C in homeless people: reaching a hard-to-reach population

DOI: 10.17235/reed.2021.7737/2020

Editorial

Screening guide for hepatitis C virus infection in Spain

DOI: 10.17235/reed.2020.7728/2020

Special Article

Strategy for the Elimination of Hepatitis C in Cantabria

DOI: 10.17235/reed.2020.7108/2020

Editorial

Reflex testing. A key tool for the elimination of hepatitis C

DOI: 10.17235/reed.2020.7201/2020

Original

Quality of life study in asymptomatic patients with hepatitis C

DOI: 10.17235/reed.2019.6339/2019

Letter

Acute seronegative hepatitis C: two case reports

DOI: 10.17235/reed.2019.5921/2018

Letter

Dyspepsia, functional dyspepsia and Rome IV criteria

DOI: 10.17235/reed.2018.5599/2018

Citation tools
Calleja Panero J, Lens García S, Fernández Bermejo M, Crespo J. Definition of the profiles of hepatitis C virus patients based on the identification of risky practices in Spain. 6169/2019


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 330 visits.
This article has been downloaded 182 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 12/01/2019

Accepted: 25/07/2019

Online First: 17/09/2019

Published: 03/10/2019

Article revision time: 114 days

Article Online First time: 248 days

Article editing time: 264 days


Share
This article has been rated by 1 readers.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology